Cornerstone Pharmaceuticals Revenue
Pharmaceutical Manufacturing • 
Cranbury, New Jersey, United States • 11-20 Employees
Cornerstone Pharmaceuticals revenue & valuation
| Annual revenue | $9,817,891 |
| Revenue per employee | $491,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $31,500,000 |
| Total funding | No funding |
Key Contacts at Cornerstone Pharmaceuticals
Jenna Vadas
Executive Director Of Finance
Patrick Wilmerding
Non-Executive Director
Mohammad Arif
Director Clinical Operations
Robert Shorr
Ceo
Robert Shorr
Founder
Steve Carchedi
Ceo
Company overview
| Headquarters | 520 Broad Street, Cranbury, NJ 07102, US |
| Phone number | +16094097050 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Keywords | Oncology |
| Employees | 11-20 |
| Socials |
Cornerstone Pharmaceuticals Email Formats
Cornerstone Pharmaceuticals uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@cornerstonepharma.com), used 62.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@cornerstonepharma.com | 62.5% |
{first initial}.{last name} | j.doe@rafaelpharma.com | 37.5% |
About Cornerstone Pharmaceuticals
We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer. Our research in the field of altered cancer metabolism directed therapies has led to the discovery of novel, first-in-class drugs and drug delivery technologies that have the potential to revolutionize cancer treatment. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues. By attacking regulatory processes that are unique to cancer and not found in healthy cells we aim to significantly improve the safety profile and efficacy of cancer treatment. CPI-613, the lead drug from our Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is currently being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent, as well as in combination with standard drug therapy.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Cornerstone Pharmaceuticals has 15 employees across 10 departments.
Departments
Number of employees
Funding Data
Cornerstone Pharmaceuticals has never raised funding before.
Cornerstone Pharmaceuticals Tech Stack
Discover the technologies and tools that power Cornerstone Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
CDN
CDN
SEO
JavaScript libraries
Tag managers
Miscellaneous
Programming languages
Miscellaneous
Analytics
Analytics
Blogs
JavaScript libraries
Morocco
Ireland
Slovenia
Portugal
Frequently asked questions
4.8
40,000 users
